No biomarker	Oral Cancer	No biomarker	Oral Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
PD-L1 expression	Oral Cancer	PD-L1 expression	Oral Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	cisplatin + paclitaxel + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + paclitaxel + 5-fluorouracil Sensitive : A2	cisplatin + paclitaxel + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + paclitaxel + 5-fluorouracil Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	docetaxel Sensitive: A2 - Guideline docetaxel Sensitive : A2	docetaxel Sensitive: A2 - Guideline docetaxel Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	cisplatin + docetaxel Sensitive: A2 - Guideline cisplatin + docetaxel Sensitive : A2	cisplatin + docetaxel Sensitive: A2 - Guideline cisplatin + docetaxel Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	carboplatin + paclitaxel Sensitive: A2 - Guideline carboplatin + paclitaxel Sensitive : A2	carboplatin + paclitaxel Sensitive: A2 - Guideline carboplatin + paclitaxel Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	afatinib Sensitive: A2 - Guideline afatinib Sensitive : A2	afatinib Sensitive: A2 - Guideline afatinib Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	cisplatin + docetaxel + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + docetaxel + 5-fluorouracil Sensitive : A2	cisplatin + docetaxel + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + docetaxel + 5-fluorouracil Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	cisplatin + paclitaxel Sensitive: A2 - Guideline cisplatin + paclitaxel Sensitive : A2	cisplatin + paclitaxel Sensitive: A2 - Guideline cisplatin + paclitaxel Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	cisplatin + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + 5-fluorouracil Sensitive : A2	cisplatin + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + 5-fluorouracil Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	5-fluorouracil + hydroxyurea Sensitive: A2 - Guideline 5-fluorouracil + hydroxyurea Sensitive : A2	5-fluorouracil + hydroxyurea Sensitive: A2 - Guideline 5-fluorouracil + hydroxyurea Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	carboplatin + 5-fluorouracil Sensitive: A2 - Guideline carboplatin + 5-fluorouracil Sensitive : A2	carboplatin + 5-fluorouracil Sensitive: A2 - Guideline carboplatin + 5-fluorouracil Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	pembrolizumab + cetuximab Sensitive: A2 - Guideline pembrolizumab + cetuximab Sensitive : A2	pembrolizumab + cetuximab Sensitive: A2 - Guideline pembrolizumab + cetuximab Sensitive : A2
GDF15 overexpression	Oral Cancer	GDF15 overexpression	Oral Cancer	TPF Sensitive: C3 – Early Trials TPF Sensitive : C3	TPF Sensitive: C3 – Early Trials TPF Sensitive : C3
POU5F1 overexpression + NANOG overexpression	Oral Cancer	POU5F1 overexpression + NANOG overexpression	Oral Cancer	cisplatin Resistant: C3 – Early Trials cisplatin Resistant : C3	cisplatin Resistant: C3 – Early Trials cisplatin Resistant : C3
miR-1290-L	Oral Cancer	miR-1290-L	Oral Cancer	5-fluorouracil Sensitive: C3 – Early Trials 5-fluorouracil Sensitive : C3	5-fluorouracil Sensitive: C3 – Early Trials 5-fluorouracil Sensitive : C3
KRAS mutation	Oral Cancer	KRAS mutation	Oral Cancer	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3
PD-L1 overexpression	Oral Cancer	PD-L1 overexpression	Oral Cancer	nivolumab + MGCD516 Sensitive: C3 – Early Trials nivolumab + MGCD516 Sensitive : C3	nivolumab + MGCD516 Sensitive: C3 – Early Trials nivolumab + MGCD516 Sensitive : C3
PD-L1 overexpression	Oral Cancer	PD-L1 overexpression	Oral Cancer	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3
PD-L1 overexpression	Oral Cancer	PD-L1 overexpression	Oral Cancer	pazopanib Sensitive: C3 – Early Trials pazopanib Sensitive : C3	pazopanib Sensitive: C3 – Early Trials pazopanib Sensitive : C3
PD-L1 overexpression	Oral Cancer	PD-L1 overexpression	Oral Cancer	paclitaxel Sensitive: C3 – Early Trials paclitaxel Sensitive : C3	paclitaxel Sensitive: C3 – Early Trials paclitaxel Sensitive : C3
PD-L1 overexpression	Oral Cancer	PD-L1 overexpression	Oral Cancer	docetaxel Sensitive: C3 – Early Trials docetaxel Sensitive : C3	docetaxel Sensitive: C3 – Early Trials docetaxel Sensitive : C3
CHEK2 mutation	Tongue Carcinoma	CHEK2 mutation	Tongue Carcinoma	ABT-888 + M6620 Sensitive: C4 – Case Studies ABT-888 + M6620 Sensitive : C4	ABT-888 + M6620 Sensitive: C4 – Case Studies ABT-888 + M6620 Sensitive : C4
FGFR2 P253R	Tongue Carcinoma	FGFR2 P253R	Tongue Carcinoma	cetuximab Sensitive: C4 – Case Studies cetuximab Sensitive : C4	cetuximab Sensitive: C4 – Case Studies cetuximab Sensitive : C4
FGFR2 P253R	Tongue Carcinoma	FGFR2 P253R	Tongue Carcinoma	pazopanib Sensitive: C4 – Case Studies pazopanib Sensitive : C4	pazopanib Sensitive: C4 – Case Studies pazopanib Sensitive : C4

Oral Cancer

Associations(51)

Associations
(51)